Combination of a fcyrllb- and a tumor antibody for use in the treatment of an fcyriib-negative cancer

Described is the use of a first antibody molecule that specifically binds Fc RIIB via its Fab region, but lacks Fc region or has reduced binding to Fc receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on a tumor cell, wh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CRAGG Mark, OLDHAM Robert, ROGHANIAN Ali, TEIGE Ingrid, BEERS Stephen, M?RTENSSON Linda, FREND?US Bj?rn
Format:	Patent
Sprache:	eng ; heb
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Described is the use of a first antibody molecule that specifically binds Fc RIIB via its Fab region, but lacks Fc region or has reduced binding to Fc receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on a tumor cell, which second antibody molecule has an Fc region that binds to at least one activating Fc receptor in the treatment of an FcγRIIB-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.